Regulation of immune responses by the neonatal Fc receptor and its therapeutic implications

Timo Rath1,2, Kristi Baker1, Michal Pyzik1 and Richard S. Blumberg1,3*

1 Department of Medicine, Division of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
2 Department of Medicine, Division of Gastroenterology, Erlangen University Hospital, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany
3 Harvard Digestive Diseases Center, Boston, MA, USA

As a single receptor, the neonatal Fc receptor (FcRn) is critically involved in regulating albumin and IgG serum concentrations by protecting these two ligands from degradation. In addition to these essential homeostatic functions, FcRn possesses important functions in regulating immune responses that are equally as critical and are increasingly coming to attention. During the first stages of life, FcRn mediates the passive transfer of IgG across the maternal placenta or neonatal intestinal walls of mammals, thereby conferring passive immunity to the offspring before and after birth. In fact, FcRn is one of the very few molecules that are known to move from luminal to serosal membranes of polarized cells that form epithelial barriers of the lung and intestines. Together with FcRn’s recently explored critical role in eliciting MHC II presentation and MHC class I cross-presentation of IgG-complexed antigen, this renders FcRn capable of exerting broad and potent functions in regulating immune responses and immunosurveillance at mucosal sites. Further, it is now clear that FcRn dependent mucosal absorption of therapeutic molecules is a clinically feasible and potent novel route of non-invasive drug delivery, and the interaction between FcRn and IgG has also been utilized for the acquisition of humoral immunity at mucosal sites. In this review, we begin by briefly summarizing the basic knowledge on FcRn expression and IgG binding, then describe more recent discoveries pertaining to the mechanisms by which FcRn orchestrates IgG related mucosal immune responses and immunosurveillance at host–environment interfaces within the adult organism. Finally, we outline how the knowledge of actions of FcRn at mucosal boundaries can be capitalized for the development and engineering of powerful mucosal vaccination strategies and novel routes for the non-invasive delivery of Fc-based therapeutics.

Keywords: neonatal Fc receptor, immunoglobulin G, albumin, mucosal immunology, antigen presentation

FcRn BINDS IgG MOLECULES THROUGHOUT ADULT LIFE

FcRn, encoded by the Fgfrt gene, is an MHC class I-like transmembrane protein that requires non-covalent association with β2-microglobulin (β2-m) for proper functioning. In its best known function, FcRn binds to the CH2-CH3 interface of the IgG Fc region in a 2:1 stoichiometry (1–3). Binding between IgG and FcRn occurs in a strictly pH-dependent manner with micro- to nanomolar affinity at pH 6.5 while binding is virtually absent at pH 7.5 (4, 5). As revealed by site-directed mutagenesis, the residues Ile253, His310, and His345 of IgG are critically involved in its interaction with FcRn (4, 6–8). Consistent with such strict pH-dependent binding, the bulk of FcRn is expressed intracellularly – predominantly in endosomes – and such that the interaction between FcRn and its ligands occurs within an intracellular acidic milieu (9–12). Although originally viewed as a receptor restricted to neo- and antenatal life, it is now clear that FcRn continues to function throughout adult life and is expressed lifelong in both parenchymal cells (epithelium of the lung and intestine as well as the liver and vascular endothelium) and hematopoietic cells [monocytes, macrophages, dendritic cells (DCs), polymorphonuclear leukocytes, and B cells] in mouse and humans [as reviewed elsewhere (13–17)]. Apart from regulating and extending the serum half-life of IgG by a mechanism that is operative in DCs and endothelial cells (18–21), FcRn orchestrates IgG-based immune responses at mucosal sites. Collectively, the numerous functions of FcRn enable it to act as a sensitive regulator of mucosal immunity via bidirectional transcytosis of IgG and luminal antigens across epithelial boundaries as well as the active induction of MHC II presentation and MHC I cross-presentation pathways for the generation of antigen-specific T-cell responses.

MUCOSAL IMMUNE REGULATION AND IMMUNOSURVEILLANCE BY FcRn

Apart from being responsible for the transplacental transfer of maternal IgG to a human fetus, FcRn has been shown to mediate the bidirectional transport of IgG across all polarized epithelial barriers including those of the gastrointestinal and respiratory tract, the placenta, and the genitourinary system including kidneys (8, 22–29). Further, it has been documented that this mechanism is operative not only in humans and mice but also in rats, pigs, and non-human primates, implying that the transepithelial
IgG transport across mucosal membranes is an evolutionarily well conserved and thus important part of immune regulation. By expressing FcRn, the epithelial barrier thus gains the ability to transport IgG from the basolateral to the apical side and vice versa, or, in other words, to deliver IgG into the lumen from the tissue space and, subsequently, transport IgG-bound luminal antigens back to the lamina propria (LP). This process is of utmost importance for immune regulation at mucosal barriers and in vivo studies have impressively demonstrated that FcRn is indeed a key molecule in integrating humoral and cellular immunity and intraluminal (and thereby foreign) signals into the host intramural immune system. To mirror the situation in humans, these studies utilized humanized mice in which a human FcRn transgene (together with human β2-m) was expressed in a mouse that was devoid of mouse FcRn (30, 31). In vivo studies using the model antigen ovalbumin (OVA) demonstrated that after intravenous injection of anti-OVA IgG and subsequent oral feeding of fluorescently labeled OVA, OVA-IgG immune complexes (ICs) formed within the gastrointestinal lumen and were transported in an FcRn dependent manner into the LP where the antigen–antibody complex was taken up by CD11c+ DCs which, upon MHC II presentation of OVA epitopes, were then able to induce an antigen-specific CD4+ T-cell response (31). Of note, the mechanism of FcRn-mediated transfer of antigen-specific IgG and subsequent induction of an antigen-specific T-cell response was not limited to the intestinal tract, as nasal administration of OVA after intravenous injection of anti-OVA IgG led to a similar FcRn-mediated uptake of antigen–antibody ICs and an expansion of antigen-specific CD4+ T-cells in the nasal-associated lymphatic tissue (31). This mechanism has direct physiologic and immunopathogenic relevance: when challenged with Citrobacter rodentium – which models enteropathogenic Escherichia coli infection – mice with restricted expression of FcRn solely within the intestinal epithelium, but not FcRn deficient animals, were protected from infection but only in the presence of anti-C. rodentium IgG antibodies, consistent with IgG being a main effector molecule in the eradication of this pathogen (32–34). To mount an effective immune response against this epithelial pathogen, FcRn was shown to mediate the following processes (Figure 1): (I.) transport of pathogen-specific IgG from the systemic circulation across the epithelial barrier into the intestinal lumen, (II.) uptake of the newly formed ICs consisting of bacteria and anti-bacterial IgG and transcytosis of these into the LP, and (III.) induction of an antigen-specific immune response and T-cell expansion within regional lymphoid structures and associated peripheral tissues (34).
Thus, these studies provide direct evidence that epithelial expression of FcRn is able to link luminal and/or epithelial infectious exposures with systemic immune activation. FcRn expression in the gastric epithelium and the associated transport of pathogen-specific IgG across the gastric epithelium is also linked to the prevention of gastric colonization and invasion by the pathogens Helicobacter heilmannii and Helicobacter pylori (35). Similarly, FcRn within the genitourinary and respiratory tract enables the transmucosal transport of pathogen-specific IgG and has been associated with the prevention of viral infection, as shown in model studies mirroring herpes simplex 2 or influenza infection (24, 29).

**FcRn’s Role in Antigen Presentation by Professional Antigen-Presenting Cells at Mucosal Surfaces**

**Classical MHC II Presentation of Immune Complexed Antigen**

While the later studies mainly investigated FcRn’s function of protecting IgG from degradation (18–21, 30), and in order to account for IgG deficiency in hematopoietic cells and parenchymal cells are equally responsible for protecting IgG from degradation (18–21, 30), and in order to maintain differences in IgG levels between WT and Fcgrt−/− mice, the utilization of bone-marrow chimeric mice is an elegant approach to circumvent differences in IgG levels between WT and Fcgrt−/− mice, as previously shown (18, 19, 21).

After having shown that FcRn is expressed in professional APC in human and mouse (18, 19, 21, 31, 36–38), it was demonstrated that FcRn in DCs enhances MHC II antigen presentation and induces proliferation of antigen-specific CD4+ T-cells when antigen is presented as a multimeric IC with IgG, both in vitro and in vivo (21), and this observation was also confirmed in humans (39). Furthermore, both murine and human studies have demonstrated that ICs containing a non-FcRn-binding IHH-IgG mutant, which harbors three mutations that disable binding to FcRn (1253A, H435A, and H436A) (7), do not lead to T-cell activation (21). Importantly, the studies showed that this regulation is only observed when the IgG–antigen complex is provided as a multimeric IC, suggesting that FcRn directs the intracellular trafficking of its ligands differently depending on the valency of the bound ligands. This concept was supported by confocal microscopy showing that multimeric IgG ICs, but not IHH-IgG1 ICs or monomeric ICs, were rapidly internalized by human DCs and co-localized with FcRn first in membrane-proximal intracellular compartments, presumably early endosomes, and subsequently in LAMP1-positive lysosomes, thus indicating that FcRn directs multimeric ICs into a cellular compartment equipped with the machinery to induce MHC II antigen presentation (39). Using bone-marrow chimeric mice, it was then directly shown that the fate and also the associated serum half-life are indeed fundamentally different depending on the ligand valency. IgG present in multimeric ICs exhibited rapidly increased degradation mediated by hematopoietic cells, presumably DCs, consistent with an in vivo fate of active trafficking toward lysosomal degradation rather than FcRn-mediated recycling. However, unbound IgG or IgG in monomeric complexes were protected from degradation in an FcRn dependent manner from both hematopoietic and myeloid cells (39). Thus, these studies show that FcRn determines the fate of IgG depending on the nature of the ligand. In a more general sense, these findings illustrate that FcRn actively senses whether an antigen has already been IgG opsonized, in which case the IC are routed towards antigen presentation compartments, or whether IgG is unbound and thus should be protected from degradation.

**MHC I Cross-Presentation of Immune Complexed Antigen**

Recent studies further extend the understanding of the critical involvement of FcRn in antigen presentation at mucosal surfaces. Strikingly, CD8−CD11b+ DCs loaded with IgG-complexed OVA induced robust proliferation of adoptively transferred OT-I T-cells in an entirely FcRn-dependent manner (36). These studies were the first to discover that FcRn exhibits also a fundamental role in the presentation of exogenous antigen to CD8+ T-cells, a process called cross-presentation (36, 40). These studies also demonstrated that FcRn within CD8−CD11b+ DCs directed the IgG ICs into a Rab27a, vacuolar ATPase, and gp91phox containing acidic phagosome that allowed for cross-presentation (36). Further, utilizing antibodies that have no affinity for FcRn, but intact affinity for canonical FcγRs (IHH-IgG) or which cannot bind FcγRs, but retain the ability to bind FcRn [N297A-IgG (41)], it was shown that canonical FcγRs on the surface of DCs mediate the entry of the ICs into the cell which then are further directed and trafficked in an FcRn dependent fashion as outlined above (36). Thus, FcRn and canonical surface FcγR’s cooperate in inducing antigen presentation and the pH-dependent ligand binding of FcRn and its expression within the acidic milieu of endosomal compartments is perfectly suited to further handle, traffic and process IgG and ICs once bound at neutral pH by FcγRs and internalized.

The mechanisms and pathophysiological significance of FcRn dependent cross-presentation to DCs at mucosal surfaces has recently been analyzed (37). First, these studies demonstrated that untreated Fcgrt−/− mice exhibit decreased numbers of CD8+ T-cells within the LP of the large intestine, and that these were also deficient in cytokine production. The utilization of CD11c−/−Fcgrt−/− mice (37) has shown that FcRn expression in DCs is critical for this. Second, FcRn within DCs was not only shown to be required for homeostatic CD8+ T-cell activation but also conferred protection from cancer development at mucosal sites, namely, the large intestine and the lung. This was reliant on the FcRn dependent induction of endogenous CD8+ T-cells towards cognate tumor antigens, and thus, these studies were the first to identify a deep involvement of FcRn in the protection from cancers arising at mucosal tissues. As an additional mechanism behind these observations, cross-linking of FcRn by IgG IC induced secretion of the cytotoxicity-promoting cytokine IL-12, thereby providing an additional stimulus to activate antigenically primed specific CD8+ T-cells (37). Importantly, analysis of the overall microbial community composition and diversity from wildtype and Fcgrt−/− littermates revealed no significant differences in either post-weaning, 8-week-old mice or pre-weaning, 2-week-old mice in any of three separate intestine-associated tissue...
compartments, thereby confirming that the induction of mucosal CD8+ T-cells in FcRn bearing mice was not due to changes in the intestinal microbiota (37).

These findings are directly translatable to human pathology such that human DCs expressing high levels of FcRn co-localize with CD8+ T-cells in the stroma of both normal and colorectal cancer (CRC) large intestine and induce IL-12 production in an FcRn-dependent manner. Further, survival analysis indicated that CRC patients with ≥10 FcRn+CD11c+ cells per observed area had significantly longer survival times over a 70-month follow up than those with <10 FcRn+CD11c+ cells in the tumor microenvironment (37). Finally, this mechanism was shown to be amenable to therapeutic manipulation. When ICs were formed with an engineered IgG variant known to exhibit enhanced FcRn binding with maintained pH dependency (42), antigen-specific CD8+ T-cell activation was induced at antigen concentrations 10-fold lower than that observed with native IgG IC, thereby demonstrating that targeting the immunostimulatory potential of FcRn using complexes formed with IgG variants having increased FcRn binding (15) and which are restricted to a single defined tumor antigen is a tractable and effective anti-tumor therapeutic approach (37). Further, proof-of-principle experiments demonstrated that *ex vivo* priming of CD8+ T-cells towards a single FcRn-targeted antigen expressed by tumor cells enables subsequent *in vivo* protection from the seeding of lung metastases. These studies demonstrate the potential of therapeutically promoting tumor immune surveillance in healthy, high-risk individuals by enhancing the baseline cytotoxic potential of the intestine by targeting and modulating FcRn binding to IgG (37).

**FcRn DEPENDENT NON-INVASIVE MUCOSAL DRUG DELIVERY AND MUCOSAL VACCINATION STRATEGIES**

FcRn is one of the few molecules known to move from the luminal to serosal membranes of the polarized cells that form the epithelial barriers of the lung and intestine (16, 43), thereby providing unique opportunities for potent non-invasive delivery of protein therapeutics across mucosal interfaces. This non-invasive mucosal drug delivery approach capitalizes upon two important prerequisites: (i) the knowledge that FcRn is functionally expressed throughout adult life in the upper and central airways as well as intestines of humans and non-human primates (8, 9, 44, 45) (ii) the knowledge that FcRn binds to the Fc portion of IgG in a pH-dependent manner and prevents degradation of monomeric ligand. Thus, when linked to an Fc fragment, therapeutic molecules benefit from both FcRn dependent half-life extension (15) and also mucosal absorption across epithelial boundaries.

The first study successfully demonstrating FcRn dependent delivery of an Fc containing therapeutic was performed in mice with a fusion protein between mouse erythropoietin (Epo) and the Fc fragment of mouse IgG1, showing that bioactive Fc-Epo fusion protein was successfully absorbed FcRn dependently via the respiratory epithelium (8). In subsequent studies in non-human primates, pulmonary delivery of a human Epo Fc-fusion protein was also successfully accomplished when the fusion proteins were aerosolized with a particle size of 4–6 mm to target the upper airways (44). In both mice and monkeys, the FcRn-dependence of this transepithelial transport was proven by the demonstration that an EpoFc-fusion containing the non-FcRn binding IHH variant of IgG was only poorly absorbed (44). In addition to that, it has already been demonstrated that this pathway is also operative in humans. A phase I clinical trial assessing the efficacy of the delivery of an Epo Fc-fusion protein into the bloodstream after administration of the fusion protein in the upper airways was able to show a dose-dependent uptake of the fusion protein with retained biologic activity (46). These studies laid the foundation for the broader possibility of transepithelial delivery of different types of Fc-fused macromolecular cargo including interferon-α, interferon-β, follicle-stimulating hormone, and nanoparticles (47–50). Thus, these studies demonstrate that FcRn-dependent drug delivery across mucosal surfaces is a novel non-invasive delivery approach that is both potent and clinically feasible.

Interestingly, exploitation of this mechanism is not necessarily restricted to the adult organism. Using a murine model of beta-glucuronidase (GUS) deficiency, in which glycosaminoglycan storage begins in prenatal life, it was shown that a GUS-Fc-fusion protein, infused into the mothers, was transported across the placenta into the fetus, leading to reduced lysosomal storage disease only in those mice whose mothers were administered GUS-Fc (51). While this approach outline that FcRn binding to the Fc region of IgG might be exploited in severe cases for the administration of Fc-based treatment strategies starting *in utero*, these studies clearly imply that pathogenic antibodies can also cross the maternal–fetal barrier. That this is indeed the case has been shown in a murine model of fetal and neonatal immune thrombocytopenia (FNT) in which FcRn-mediated transplacental transfer of maternal pathogenic antibodies results in the destruction of platelets in the neonate (52) but saturation of FcRn by intravenous infusion of IgG (IVIG) or blocking of FcRn in the mother prevented antibody-mediated FNIT (53). Apart from pathogenic antibodies, virion-IgG complexes, as demonstrated for cytomegalovirus, can disseminate in the placenta and gain access to the fetal circulation by co-opting the FcRn-mediated transplacental IgG transport pathway (54). Collectively, these studies demonstrate that the relevance of FcRn’s functions in the placenta extend far beyond the simple acquisition of passive immunity but also have broad implications for understanding neonatal (patho)immunology and the development of novel treatment strategies.

As shown recently, the interaction between FcRn and IgG can not only be co-opted for novel and non-invasive drug delivery approaches but also for the induction of humoral immunity along mucosal barriers. FcRn’s ability to confer humoral immunity is based on its capacity to bidirectionally transcytose IgG molecules across the epithelium lining mucosal barriers and preliminary studies have successfully demonstrated that FcRn conferred protective passive humoral immunity against infections at the site of pathogen entry when neutralizing antibodies were administered to the systemic circulation before infection (24, 29, 35). This was shown *in vivo* for both bacterial and viral agents, where FcRn-mediated translocation of systemically administered pathogen-specific IgG to the mucosal site of pathogen entry within the gastrointestinal or genital tract was identified as the key mechanism responsible for protection (24, 29, 35).

In addition to passive immunity, it has already been demonstrated *in vivo* that FcRn can also confer active humoral immunity.
Table 1 | Therapeutic applications and opportunities derived from FcRn-based biology.

| FcRn-based therapeutic approaches | Mode of action | Therapeutic use | Reference |
|----------------------------------|---------------|----------------|-----------|
| **TRANSPORTING IgG**             |               |                |           |
| Respiratory epithelium           | Transcytosis of IgG across respiratory epithelium | Non-invasive pulmonary delivery of IgG-based therapeutics in non-human primates and humans | (8, 44–46) |
|                                  |               | Vaccination against respiratory pathogens |           |
| Intestinal epithelium           | Transcytosis of IgG across intestinal epithelium | Providing passive and active immunity against enteric pathogens and infections | (31, 34, 35) |
|                                  | Transepithelial transport of Fc-targeted nanoparticles | Enabling drugs currently limited by low bioavailability to be efficiently delivered through oral administration |           |
| Genitourinary epithelium        | Transcytosis of IgG across genitourinary epithelium | Providing passive and active immunity against infections with genitourinary entrance | (55, 56) |
| Placenta                         | Transcytosis of IgG across the placenta from mother to fetus | Providing passive immunity to fetus | (51–53, 59–61) |
|                                  |               | Transplacental delivery of IgG-based therapeutics |           |
| **REGULATING IgG HALF-LIFE**     |               |                |           |
| Extending serum half-life of IgG | Increasing FcRn binding with selective mutations within the IgG Fc fragment that enable pH-dependent binding of IgG | Increasing bioavailability of IgG- and IgG-based therapeutics in serum and tissue, effectiveness shown for | (42, 62–66) |
| and IgG-based therapeutics       |               | Prolonging factor VIII and IX serum half-life for hemophilia treatment |           |
| by augmenting FcRn interactions  |               | Enhanced anti-tumor activity |           |
|                                  |               | Protection against (S)HIV |           |
|                                  | Increasing FcRn binding to multimeric IgG containing immune complexes | Increasing and inducing MHC I and MHC II antigen presentation | (21, 31, 34, 36, 37, 67) |
|                                  |               | Increasing and inducing antigen-specific T-cell responses |           |
|                                  |               | Relevance and effectiveness shown for |           |
|                                  |               | Tumor protection at mucosal sites (intestines, lung) |           |
|                                  |               | Vaccination with tumor antigen for increased anti-tumor surveillance |           |
| Reducing serum half-life of IgG- | IVIG effect and saturating FcRn binding | Amelioration of IgG-mediated diseases such as | (15, 19, 68–78) |
| and IgG-based therapeutics       | Peptide mimetics or anti-FcRn antibodies that block IgG binding Engineered antibodies with higher FcRn affinity that enhance IgG degradation (Abdegs) | Immune thrombocytopenic purpura |           |
|                                  |               | Myasthenia gravis |           |
|                                  |               | Colitis |           |
|                                  |               | Arthritis |           |
|                                  |               | Pemphigus vulgaris |           |
|                                  |               | Autoimmune encephalomyelitis |           |
|                                  |               | Lupus nephritis |           |

A prerequisite in these studies was that pathogens were, in order to enable FcRn-mediated transport of the antigen across the mucosal barrier, presented as Fc-fusion proteins and were administered in the presence of potent adjuvants to force an immune response. Intranasal immunization with a fusion protein between herpes simplex virus type-2 (HSV-2) glycoprotein G and the Fc domain of IgG2a together with the adjuvant CpG, protected wild type, but not FcRn knockout, mice after intravaginal challenge with virulent HSV-2 and this immunization strategy induced an efficient mucosal and systemic antibody response as well B- and T-cell immunity (55). Similarly, mice that were intranasally vaccinated with a fusion protein between HIV Gag p24 and the Fc of mouse IgG2a together with CpG as an adjuvant developed local and systemic immunity, including durable B- and T-cell memory. In these experiments, Gag-specific immunity was sufficiently potent to protect against an intravaginal challenge with recombinant vaccine virus expressing the HIV Gag protein (56). Of particular importance, mice lacking FcRn or those immunized with free antigen or an antigen fused to an Fc fragment disabled in FcRn binding were not protected against HSV or HIV infection, thereby highlighting the central role of FcRn and its intact binding to IgG for efficient mucosal transport across an epithelial barrier and the elicitation of active mucosal immunization (55, 56). Finally, as shown in transgenic animals, overexpression of FcRn...
can significantly enhance humoral immunity by the following mechanisms: (i) prolonged IgG half-life, (ii) facilitation of antigen presentation by antigen-presenting cells (APCs), resulting in increased antigen-specific humoral immune response with larger numbers of antigen-specific B cells, and (iii) generation of antibodies against weakly immunogenic antigens, as recently reviewed elsewhere (57). Table 1 summarizes therapeutic applications and opportunities derived from FcRn-based biology.

CONCLUDING REMARKS

In the recent past, the view of FcRn has changed from a receptor that is deeply involved in antigen presentation pathways. It is now clear that FcRn inherits a fundamental role in classical MHC II presentation of exogenous antigen as well as in the cross-presentation of exogenous antigen on MHC I molecules. The pleiotropic functions enable FcRn to elicit antigen-specific CD4+ and CD8+ T-cell responses and thus exert broad functions in immune surveillance and immune homeostasis. Critically, these pathways have already been shown to have important pathophysiologic relevance for infectious diseases and cancer development along mucosal barriers. Exploitation of the receptor–ligand interaction between FcRn and IgG has already been successfully used for the development of novel mucosal vaccination strategies as well as the non-invasive delivery of Fc-fusion proteins. Thus, the roles that FcRn plays in guiding the transport of IgG across epithelial barriers and regulating the recycling of monomeric IgG away from a degradative fate in lysosomes and preserving IgG half-life or alternatively directing IgG containing ICs to the antigen presentation machinery present enormous therapeutic opportunities for translation (Table 1). Our increasing understanding of the biology of FcRn will likely only increase the range of therapeutic applications for FcRn-targeted drugs, which promise to deliver effective treatment for neoplastic, infectious, and autoimmune diseases.

REFERENCES

1. Huber AH, Kelley RF, Gastinel LN, Bjorkman PJ. Crystalization and stoichiometry of binding of a complex between a rat intestinal Fc receptor and Fc. J Mol Biol (1993) 230:1077–83. doi:10.1006/jmbi.1993.1220
2. Sanchez LM, Penny DM, Bjorkman PJ. Stoichiometry of the interaction between the major histocompatibility complex-related Fc receptor and its Fc ligand. Biochemistry (1999) 38:9471–6. doi:10.1021/bi9907330
3. Schuck P, Radu CG, Ward ES. Sedimentation equilibrium analysis of recombinant mouse FcRn with murine IgG1. Mol Immunol (1999) 36:1117–25. doi:10.1016/S0161-5890(99)00093-0
4. Raghavan M, Bonagara VR, Morrison SL, Bjorkman PJ. Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. Biochemistry (1995) 34:14649–57. doi:10.1021/bi00045a005
5. Raghavan M, Chen MY, Gastinel LN, Bjorkman PJ. Investigation of the interaction between the major histocompatibility complex-related Fc receptor and its immunoglobulin G ligand. Immunity (1994) 1:303–15. doi:10.1016/1074-7613(94)90082-5
6. Medesan C, Cianga P, Mummert M, Stanescu D, Ghetie V, Ward ES. Comparative studies of rat IgG to further delineate the FcRn-FcG interaction site. Eur J Immunol (1998) 28:2092–100. doi:10.1002/(SICI)1521-4141(199807)28:07<2092::AID-IMMU2992>3.0.CO;2-E
7. Medesan C, Mateoi D, Radu C, Ghetie V, Ward ES. Delination of the amino acid residues involved in transcytosis and catabolism of mouse IgG1. J Immunol (1997) 158:2211–7.
8. Spiekermann GM, Finn PW, Ward ES, Dumont J, Dickinson BL, Blumberg RS, et al. Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. J Exp Med (2002) 196:303–10. doi:10.1084/jem.20020400
9. Dickinson BL, Badizadegan K, Wu Z, Ahouse JC, Zhu X, Simister NE, et al. Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J Clin Invest (1999) 104:903–11. doi:10.1172/JCI86968
10. Ober RJ, Martinez C, Vaccaro C, Zhou J, Ward ES. Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn. J Immunol (2004) 172:2021–9. doi:10.4049/jimmunol.172.4.2021
11. Ward ES, Martinez C, Vaccaro C, Zhou J, Tang Q, Ober RJ. From sorting endosomes to cytosolic: association of Rab5 and Rab11 GTPases with the Fc receptor, FcRn, during recycling. Mol Biol Cell (2005) 16:2028–38. doi:10.1091/mbc.E04-08-0735
12. Ward ES, Zhou J, Ghetie V, Ober RJ. Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans. Int Immunol (2003) 15:187–95. doi:10.1093/intimm/dxg018
13. Andersen JT, Sandlie I. The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics. Drug Metab Pharmacokinet (2009) 24:318–32. doi:10.2133/dmpk.24.318
14. Baker K, Rath T, Fyzik M, Blumberg RS. The role of FcRn in antigen presenta- tion. Front Immunol (2014) 5:408. doi:10.3389/fimmu.2014.00408
15. Rath T, Baker K, Dumont JA, Peters RT, Jiang H, Qiao SW, et al. Fc-fusion pro- teins and FcRn: structural insights for longer-lasting and more effective therapeutics. Crit Rev Biotechnol (2013). doi:10.3109/07388551.2013.834293
16. Rath T, Kuo TT, Baker K, Qiao SW, Kobayashi K, Yoshida M, et al. The immuno- logic functions of the neonatal Fc receptor for IgG. J Clin Immunol (2013) 33(Suppl 1):59–17. doi:10.1007/s10875-012-9768-y
17. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol (2007) 7:115–25. doi:10.1038/nri2155
18. Akilesh S, Christianson CJ, Roopenian DC, Shaw AS. Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism. J Immunol (2007) 179:4580–8. doi:10.4049/jimmunol.179.7.4580
19. Kobayashi K, Qiao SW, Yoshida M, Baker K, Lencer WI, Blumberg RS. An FcRn-dependent role for anti-flagelin immunoglobulin G in pathogenesis of colitis in mice. Gastroenterology (2009) 137(1746–1756):e1741. doi:10.1053/j.gastro.2009.07.059
20. Montoyo HP, Vaccaro C, Hafner M, Ober RJ, Mueller W, Ward ES. Condi- tional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice. Proc Natl Acad Sci USA (2009) 106:2788–93. doi:10.1073/pnas.0810796106
21. Qiao SW, Kobayashi K, Johansen JT, Sollid LM, Andersen JT, Milford E, et al. Dependence of antibody-mediated presentation of antigen on FcRn. Proc Natl Acad Sci USA (2008) 105:9537–42. doi:10.1073/pnas.0801717105
22. Akilesh S, Huber TB, Wu H, Wang G, Hartleben B, Kopp JB, et al. Podocyte use of functionally active FcRn and the differentiated bidirectional transport of IgG in human placental endothelial cells. Hum Immunol (2001) 62:93–105. doi:10.1016/S0198-8859(00)00145-4
23. Bai Y, Le T, Tsear DB, Song H, Zhao D, Björkman PJ, et al. Intracellular neutraliza- tion of viral infection in polarized epithelial cells by neonatal Fc receptor (FcRn)-mediated IgG transport. Proc Natl Acad Sci USA (2011) 108(45):18406–11. doi:10.1073/pnas.1115348110
24. Claypool SM, Dickinson BL, Wagner JS, Johansen FE, Venu N, Borawski JA, et al. Bidirectional transepithelial IgG transport by a strongly polarized basolateral Fcgamma-receptor. Mol Biol Cell (2004) 15:1746–59. doi:10.1091/mbc.E03-11-0832
25. Claypool SM, Dickinson BL, Yoshida M, Lencer WI, Blumberg RS. Functional reconstitution of human FcRn in Madin-Darby canine kidney cells requires co-expressed human beta 2-microglobulin. J Biol Chem (2007) 282:26038–50. doi:10.1074/jbc.M702620200
26. Ellinger I, Rothe A, Grill M, Fuchs R. Apical to basolateral recycling of immunoglobulin G in trophoblast-derived BeWo cells: a model system to study IgG trans- port in the placenta. Eur J Immunol (1999) 29:733–44. doi:10.1002/(SICI)1521- 4119(199903)29:3<733::AID-IMMU373>3.0.CO;2-C
27. Ellinger I, Schwob M, Stefanescu A, Hunziker W, Fuchs R. IgG transport across trophoblast-derived BeWo cells: a model system to study IgG tran- sport in the placenta. Eur J Immunol (2014) 29:733–44. doi:10.1002/(SICI)1521- 4119(199903)29:3<733::AID-IMMU373>3.0.CO;2-C
Baker K, Rath T, Flak MB, Arthur JC, Chen Z, Glickman JN, et al. Neonatal FcRn in mucosal immunity.

Baker K, Qiao SW, Kuo TT, Aveson VG, Platzer B, Andersen JT, et al. Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8-CD11b+ dendritic cells. Proc Natl Acad Sci U S A (2010) 107:1095–107. doi:10.1073/pnas.0908417106

Baker K, Rath T, Flak MB, Arthur JC, Chen Z, Glickman JN, et al. Neonatal Fc receptor expression in dendritic cells mediates protective immunity against colorectal cancer. Immunology (2013) 139:1095–107. doi:10.1111/imun.2013.11.003

Zhu X, Meng G, Dickinson BL, Li X, Mizoguchi E, Miao L, et al. MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocoytes, intestinal macrophages, and dendritic cells. J Immunol (2001) 166:3266–76. doi:10.4049/jimmunol.166.3.3266

Qiao SW, Bergeveng E, Molberg O, Jung G, Fleckenstein B, Sollid LM. Refining the rules of gladin T cell epitope binding to the disease-associated DQ molecule in celiac disease: importance of protein splicing and glutamine deamidation. J Immunol (2005) 175:254–61. doi:10.4049/jimmunol.175.1.254

Amigorena S, Savina A. Intracellular mechanisms of antigen cross presentation in dendritic cells. Curr Opin Immunol (2010) 22:109–17. doi:10.1016/j.coi.2010.01.022

Tao MH, Morrison SL. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol (1998) 158:2595–601.

Zalewsky J, Kleinspehn AK, Horton MJ, Hartvigsen KS, Ehrlich J, et al. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol (2010) 28:157–9. doi:10.1038/nbt.1601

Baker K, Qiao SW, Kuo TT, Kobayashi K, Yosida M, Chen HL, et al. Human placental Fc receptors and the transmigration of interferon Beta-1a-fc fusion protein in non-human primates using an immunoglobulin transport pathway. J Immunol (2012) 189:1527–31. doi:10.4049/jimmunol.1200303

Bitonti AJ, Dumont JA, Low SC, Peters RT, Kropf KE, Palombella VJ, et al. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc Natl Acad Sci U S A (2004) 101:9763–8. doi:10.1073/pnas.0403235101

Israel EJ, Taylor S, Wu Z, Mizoguchi E, Blumberg RS, Bhan A, et al. Expression of the neonatal Fc receptor, FcRn, on human intestinal epithelial cells. Immunology (1997) 92:69–74. doi:10.1046/j.1365-2664.1997.00326.x

Dumont JA, Bitonti AJ, Clark D, Evans S, Pickford M, Newman SP. Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway. J Aerosol Med (2005) 18:294–303. doi:10.1089/am.2005.18.294

Bitonti AJ, Dumont JA. Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway. Adv Drug Deliv Rev (2006) 58:1106–18. doi:10.1016/j.addr.2006.07.015

Low SC, Nunes SL, Bitonti AJ, Dumont JA. Oral and pulmonary delivery of FSH-Fc fusion proteins via neonatal Fc receptor-mediated transcytosis. Hum Reprod (2005) 20:1805–13. doi:10.1093/humrep/deh896

Vallee S, Rakhe S, Reidy T, Walker S, Li Q, Sakorasas P, et al. Pulmonary administration of interferon Beta-1a-fc fusion protein in non-human primates using an immunoglobulin transport pathway. J Interferon Cytokine Res (2012) 32:178–84. doi:10.1089/jir.2011.0048

Pridgen EM, Alessio F, Kuo TT, Levy-Nissenbaum E, Karknish, Blumberg RS, et al. Transepithelial transport of Fc-targeted nanoparticles by the neonatal Fc receptor for oral delivery. Sci Transl Med (2013) 5:213ra167. doi:10.1126/scitranslmed.3007049

Grubb JH, Vogler C, Tan Y, Shah GN, MacRae AE, Sly WS. Infused Fc-tagged beta-glucuronidase crosses the placenta and produces clearance of storage in utero in mucopolysaccharidosis VII mice. Proc Natl Acad Sci U S A (2008) 105:8375–80. doi:10.1073/pnas.0803715105

Chen P, Li C, Lang S, Zhu G, Reheman A, Spring CM, et al. Animal model of fetal and neonatal immune thrombocytopenia: role of neonatal Fc receptor in the pathogenesis and therapy. Blood (2010) 116:3660–8. doi:10.1182/blood-2010-05-284919

Li C, Piran S, Chen P, Lang S, Zarppelin A, Jin JW, et al. The maternal immune response to fetal platelet GPIb alpha causes frequent miscarriage in mice that can be prevented by intravenous IgG and anti-FcRn therapies. J Clin Invest (2011) 121:4537–47. doi:10.1172/JCI75850

Madjid E, McDonagh S, Genbacev O, Tabata T, Pereira L. Maternal antibodies enhance or prevent cytomegalovirus infection in the placenta by neonatal Fc receptor-mediated transcytosis. Am J Pathol (2006) 168:1210–26. doi:10.2353/ajpath.2006.050482

Ye L, Zeng, R Bai, Roopenian DC, Zhu X. Efficient mucosal vaccination mediated by the neonatal Fc receptor. Nat Biotechnol (2011) 29:158–63. doi:10.1038/nbt.1742

Lu L, Palaniyandi S, Zeng R, Bai Y, Liu X, Wang Y, et al. A neonatal Fc receptor-targeted mucosal vaccine strategy effectively induces HIV-1 antigen-specific immunity to genital infection. J Virol (2011) 85:10542–53. doi:10.1128/JVI.05441-11

Kacskovics I, Cervenak J, Erdei A, Goldsby RA, Butler JE. Recent advances using FcRn to control IgG pharmacokinetics in the neonatal period. J Aerosol Med (2005) 18:9763–8. doi:10.1182/blood-2013-10-529974

Leach JL, Sedmak DM, Osborne JM, Rahil B, Lairmore MD, Anderson CL. Iso- lation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: implications for maternal-fetal antibody transport. J Immunol (1996) 157:3317–22.

Simister NE, Story CM. Human placental Fc receptors and the transmission of antibodies from mother to fetus. J Reprod Immunol (1997) 37:1–23. doi:10.1016/S0165-3803(96)00065-8

Simister NE, Story CM, Chen HL, Hunt JS. An IgG-facilitating Fc receptor expressed in the syncytiotrophoblast of human placenta. Eur J Immunol (1996) 26:1527–9. doi:10.1002/eji.1830260718

Dumont JA, Liu T, Low SC, Zhang X, Kamphuis, G, Sakorasas P, et al. Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A patients. J Blood Med (2012) 3:19256–61. doi:10.4161/jbme.2012.85544

Mahlangu J, Powell JS, Ragni MV, Chowdary P, Josephson NC, Pabinger I, et al. Phase 3 study of recombinant factor VIII-Fc fusion protein in severe hemophilia A. Blood (2014) 123:317–25. doi:10.1182/blood-2013-10-529974

Powell JS, Pasi KJ, Ragni MV, Ozelo MC, Valenti J, Pabinger I, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med (2013) 369:2313–23. doi:10.1056/NEJMoa1305747

Powell JS, Josephson NC, Clark D, Evans S, Pickford M, Newman SP, et al. Safety and prolonged activity of recombinant factor A-Fc fusion protein in hemophilia A patients. Blood (2012) 119:3031–7. doi:10.1182/blood-2011-09-382846

Shapiro AD, Ragni MV, Valenti JA, Key NS, Josephson NC, Powell JS, et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood (2012) 119:666–7. doi:10.1182/blood-2011-07-367003
67. Baker K, Rath T, Lencer WI, Fiebig E, Blumberg RS. Cross-presentation of IgG-containing immune complexes. *Cell Mol Life Sci* (2013) 70(8):1319–34. doi:10.1007/s00018-012-1100-8

68. Akilesh S, Petkova S, Sproule TJ, Shaffer DJ, Christianson GI, Roopenian D. The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. *J Clin Invest* (2004) 113:1328–33. doi:10.1172/JCI18838

69. Hansen RJ, Balthasar JP. Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. *Thromb Haemost* (2002) 88:898–9.

70. Ni L, Zhao M, Hilario-Vargas J, Prisayanh P, Warren S, Diaz LA, et al. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. *J Clin Invest* (2005) 115:3440–50. doi:10.1172/JCI24394

71. Liu L, Garcia AM, Santoro H, Zhang Y, McDonnell K, Dumont J, et al. Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockage. *J Immunol* (2007) 178:5390–8. doi:10.4049/jimmunol.178.8.5390

72. Liu Z, Roopenian DC, Zhou X, Christianson GI, Diaz LA, Sedmak DD, et al. Beta2-microglobulin-deficient mice are resistant to bullous pemphigoid. *J Exp Med* (1997) 186:777–83. doi:10.1084/jem.186.5.777

73. Nimmerjahn F, Ravetch JV. The antiinflammatory activity of IgG: the intravenous IgG paradox. *J Exp Med* (2007) 204:11–5. doi:10.1084/jem.20061788

74. Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. *Annu Rev Immunol* (2008) 26:513–33. doi:10.1146/annurev.immunol.26.021607.090232

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 22 August 2014; accepted: 10 December 2014; published online: 05 January 2015.

Citation: Rath T, Baker K, Pyzik M and Blumberg RS (2015) Regulation of immune responses by the neonatal Fc receptor and its therapeutic implications. *Front. Immunol.* 5:664. doi: 10.3389/fimmu.2014.00664

This article was submitted to Immunotherapies and Vaccines, a section of the journal *Frontiers in Immunology.*

Copyright © 2015 Rath, Baker, Pyzik and Blumberg. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.